Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.

NCT07377786 | Not Yet Recruiting DMC

• 1 other identifier: Soh-Med-25-12-9MS
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate the prognostic values of platelet indices and inflammatory markers in patients with HELLP syndrome as:- :-Primary outcome To investigate prognostic values of platelet indices and. . inflammatory markers in HELLP syndrome patients as main indices including (NLR-PLR-MPV-PDW and RDW). .

• Secondary outcome. Evaluation complications of HELLP syndrome including. .
• Maternal complication:- eclampsia, disseminated intravascular coagulation (DIC), liver rupture, placental abruption, stroke, and pulmonary or kidney failure. .
• Fetal complication:-intra uterine fetal death(iufd) ,neonate need for admission to NICU , congintal anomalies .assess APGAR score (which assess appearance(skin color)-pulse(heart rate)-Grimace(reflex irritability)- Activity(muscle tone)-Respiratory(breathing efforts) or umblical cord PH\<7. .

Conditions

HELLP Syndrome

Outcome Measures

Primary Outcomes (1)

• This study aims to evaluate the prognostic values of platelet indices and inflammatory markers in patients with HELLP syndrome

  To investigate prognostic values of platelet indices and. . inflammatory markers in HELLP syndrome patients as main indices including (NLR-PLR-MPV-PDW and RDW)

  48Hours

Secondary Outcomes (1)

• Evaluation complications of HELLP syndrome

  48 hours

Study Arms (2)

HELLP syndrome group

Pregnant patients diagnosed with HELLP syndrome enrolled prospectively to evaluate platelet indices and inflammatory markers and their prognostic value on maternal and clinical outcomes.

Diagnostic Test: Group I: 30 patients with HELLP syndrome

Healthy pregnant controlled group

Healthy pregnant women without hypertensive disorders of pregnancy recruited as a control group for comparison.

Diagnostic Test: Group I: 30 patients with HELLP syndrome

Interventions

Group I: 30 patients with HELLP syndrome DIAGNOSTIC_TEST

All patients will be subjected to the following in ICU through 48 hrs Detailed medical history taking: Demographic data (age, weight, height, body mass index (BMI). Physical examination (conscious level-vital signs) Type of anesthesia (spinal -general anesthesia) Number of pregnancies, parity, history of previous pregnancies, smoking status, and history of assisted reproductive treatments. Laboratory investigations, indices and inflammatory markers: will be obtained after delivery, once the patient is admitted to the intensive care unit. Complete blood counts (CBC). Biochemical analyses \[such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), albumin ,bilirubin and creatinine\]. The indices include platelet count (PC), MPV, PDW, and plateletcrit (PCT), among these, PDW, an indicator of platelet size heterogeneity, is a marker of platelet function. It is being evaluated as a potential indicator for the risk prediction of

HELLP syndrome group; Healthy pregnant controlled group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: HELlP syndrome in pregnant woman
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients with HELLP syndrome in surgical intensive care unit

You may qualify if:

• Pregnant women aged 18 and 45 years. Gestational age ranged from 28 to 41 weeks. Pregnant women diagnosed with HELLP syndrome. Preeclampsia with Hellp syndrome. Pt with HELLP syndrome was delivered by ceserian section(SC)then admitted to Intensive care unit (ICU) only normal singleton pregnancies without fetal congenital or chromosomal anomalies

You may not qualify if:

• Patients with infection and fever. Women with a history of diabetes, hypertension, systemic or endocrine disorder, chronic infection, chronic renal disease Liver diseases. Blood diseases. Drugs affecting platelet counts or functions. Any history of membrane rupture

Sponsors & Collaborators

• Sohag University: lead

MeSH Terms

Conditions

HELLP Syndrome

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Central Study Contacts

Esraa Gaheen Ali, Resident

CONTACT

01066768174; esraa-jaheen-post@med.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Anesthesia,surgical Intensive Care, and Pain Management Faculty of Medicine, Sohag University

Study Record Dates

• First Submitted: January 22, 2026
• First Posted: January 30, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: January 30, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share